HRP20110331T1 - Antikoagulantno-antitrombotski dvojni inhibitori, koji sadrže biotinski biljeg - Google Patents
Antikoagulantno-antitrombotski dvojni inhibitori, koji sadrže biotinski biljeg Download PDFInfo
- Publication number
- HRP20110331T1 HRP20110331T1 HR20110331T HRP20110331T HRP20110331T1 HR P20110331 T1 HRP20110331 T1 HR P20110331T1 HR 20110331 T HR20110331 T HR 20110331T HR P20110331 T HRP20110331 T HR P20110331T HR P20110331 T1 HRP20110331 T1 HR P20110331T1
- Authority
- HR
- Croatia
- Prior art keywords
- spacer
- compound according
- oligosaccharide
- residue
- compound
- Prior art date
Links
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 title claims abstract 8
- 230000002785 anti-thrombosis Effects 0.000 title claims abstract 4
- 229960002685 biotin Drugs 0.000 title claims abstract 4
- 235000020958 biotin Nutrition 0.000 title claims abstract 4
- 239000011616 biotin Substances 0.000 title claims abstract 4
- 239000003146 anticoagulant agent Substances 0.000 title claims 3
- 229940127219 anticoagulant drug Drugs 0.000 title 1
- 230000009977 dual effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 17
- 125000006850 spacer group Chemical group 0.000 claims abstract 6
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract 5
- 239000005557 antagonist Substances 0.000 claims abstract 4
- 229920001542 oligosaccharide Polymers 0.000 claims abstract 3
- 208000007536 Thrombosis Diseases 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 108090000190 Thrombin Proteins 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 150000001615 biotins Chemical class 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
- COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 claims 1
- 229960003425 tirofiban Drugs 0.000 claims 1
- 108090001008 Avidin Proteins 0.000 abstract 1
- 102000008946 Fibrinogen Human genes 0.000 abstract 1
- 108010049003 Fibrinogen Proteins 0.000 abstract 1
- 108010090804 Streptavidin Proteins 0.000 abstract 1
- 230000001858 anti-Xa Effects 0.000 abstract 1
- 150000007942 carboxylates Chemical group 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229940012952 fibrinogen Drugs 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000001483 monosaccharide substituent group Chemical group 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Nanotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Antitrombotski spoj formule Ioligosaharid-razmaknica-antagonist GpIIb/IIIa (I), naznačen time što oligosaharid je negativno nabijeni pentasaharidni ostatak Formule Bgdje R1 je OCH3 ili OSO3, a naboj kompenziraju pozitivno nabijeni protuioni; razmaknica je farmakološki uglavnom inaktivni vežući ostatak; antagonist GpIIbIIIIa je ostatak dobiven iz tirofibana (MK 383); ili njegova farmaceutski prihvatljiva sol; gdje razmaknica u spoju formule I sadrži kovalentnu vezu s biotinskim biljegom. Patent sadrži još 9 patentnih zahtjeva.
Claims (10)
1. Antitrombotski spoj formule I
oligosaharid-razmaknica-antagonist GpIIb/IIIa (I),
naznačen time što oligosaharid je negativno nabijeni pentasaharidni ostatak Formule B
[image]
gdje R1 je OCH3 ili OSO3, a naboj kompenziraju pozitivno nabijeni protuioni;
razmaknica je farmakološki uglavnom inaktivni vežući ostatak;
antagonist GpIIbIIIIa je ostatak dobiven iz tirofibana (MK 383);
ili njegova farmaceutski prihvatljiva sol;
gdje razmaknica u spoju formule I sadrži kovalentnu vezu s biotinskim biljegom.
2. Spoj u skladu s patentnim zahtjevom 1 ili 2, naznačen time što razmaknica je duga 1-50 atoma.
3. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što razmaknica sadrži najmanje jedan element -(CH2CH2O)-.
4. Spoj u skladu s bilo kojim u skladu s patentnim zahtjevom 1-3, naznačen time što razmaknica u spoju formule I sadrži jednu kovalentnu vezu s biotinskim analogom formule -(CH2)4-X-BT, gdje X = NH, N(1-4C)alkil, NH-CH(CH2OH)-CH2-C (O)-NH, NH-CH(CH3)-CH2-C(O)-NH, NH-CH(COOH)-CH2-C(O)-NH ili NH-CH(CH2COOH)-CH2-C(O)-NH, te gdje BT je biljeg
[image]
.
5. Spoj u skladu s patentnim zahtjevom 4, naznačen time što je
[image]
.
6. Spoj u skladu s patentnim zahtjevom 5, naznačen time što je u obliku svoje soli s natrijem.
7. Spoj u skladu s patentnim zahtjevom 5, naznačen time što je
[image]
.
8. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 7 i farmaceutski prikladne pomoćne tvari.
9. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što je namijenjen upotrebi u terapiji.
10. Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje ili sprječavanje tromboze ili drugih bolesti povezanih s trombinom.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05109403 | 2005-10-10 | ||
| EP05109962 | 2005-10-25 | ||
| PCT/EP2006/067127 WO2007042469A2 (en) | 2005-10-10 | 2006-10-06 | Anticoagulant antithrombotic dual inhibitors comprising a biotin label |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110331T1 true HRP20110331T1 (hr) | 2011-06-30 |
Family
ID=37451080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110331T HRP20110331T1 (hr) | 2005-10-10 | 2011-05-06 | Antikoagulantno-antitrombotski dvojni inhibitori, koji sadrže biotinski biljeg |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1991271B1 (hr) |
| JP (1) | JP5060486B2 (hr) |
| KR (1) | KR20080055960A (hr) |
| AT (1) | ATE500849T1 (hr) |
| AU (1) | AU2006301331B2 (hr) |
| BR (1) | BRPI0617215A2 (hr) |
| CA (1) | CA2624588C (hr) |
| DE (1) | DE602006020634D1 (hr) |
| EC (1) | ECSP088443A (hr) |
| HR (1) | HRP20110331T1 (hr) |
| IL (1) | IL190523A0 (hr) |
| MY (1) | MY145269A (hr) |
| NO (1) | NO20081619L (hr) |
| NZ (1) | NZ567221A (hr) |
| PL (1) | PL1991271T3 (hr) |
| RU (1) | RU2434876C2 (hr) |
| WO (1) | WO2007042469A2 (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2145624A1 (en) * | 2008-07-18 | 2010-01-20 | Sanofi-Aventis | Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment |
| TW201006479A (en) * | 2008-07-18 | 2010-02-16 | Sanofi Aventis | Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment |
| EP2233143A1 (en) * | 2009-03-24 | 2010-09-29 | Sanofi-Aventis | Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment |
| EP2512448B1 (en) | 2009-12-18 | 2016-07-06 | Endotis Pharma | Pharmaceutical oral dosage form containing a synthetic oligosaccharide |
| EP2614089A1 (fr) * | 2010-09-10 | 2013-07-17 | Sanofi-Aventis | Polysaccharides biotinyles a activite antithrombotique et presentant une stabilite metabolique amelioree |
| ES2560467T3 (es) * | 2011-06-17 | 2016-02-19 | Carbomimetics | Pentasacáridos sintéticos que tienen vida media corta y alta actividad |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6217869B1 (en) * | 1992-06-09 | 2001-04-17 | Neorx Corporation | Pretargeting methods and compounds |
| TWI289566B (en) * | 1999-12-07 | 2007-11-11 | N.V.Organon | Antithrombotic compound |
| FR2814463B1 (fr) * | 2000-09-22 | 2002-11-15 | Sanofi Synthelabo | Nouveaux polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine |
| EP1574516A1 (en) * | 2004-03-05 | 2005-09-14 | Sanofi-Aventis | Antithrombotic compound |
-
2006
- 2006-10-06 BR BRPI0617215-6A patent/BRPI0617215A2/pt not_active IP Right Cessation
- 2006-10-06 AU AU2006301331A patent/AU2006301331B2/en active Active
- 2006-10-06 PL PL06807029T patent/PL1991271T3/pl unknown
- 2006-10-06 EP EP06807029A patent/EP1991271B1/en active Active
- 2006-10-06 KR KR1020087010058A patent/KR20080055960A/ko active IP Right Grant
- 2006-10-06 MY MYPI20081018A patent/MY145269A/en unknown
- 2006-10-06 NZ NZ567221A patent/NZ567221A/en not_active IP Right Cessation
- 2006-10-06 WO PCT/EP2006/067127 patent/WO2007042469A2/en active Application Filing
- 2006-10-06 RU RU2008118365/04A patent/RU2434876C2/ru not_active IP Right Cessation
- 2006-10-06 JP JP2008535002A patent/JP5060486B2/ja active Active
- 2006-10-06 CA CA2624588A patent/CA2624588C/en active Active
- 2006-10-06 DE DE602006020634T patent/DE602006020634D1/de active Active
- 2006-10-06 AT AT06807029T patent/ATE500849T1/de not_active IP Right Cessation
-
2008
- 2008-03-31 IL IL190523A patent/IL190523A0/en unknown
- 2008-04-02 NO NO20081619A patent/NO20081619L/no not_active Application Discontinuation
- 2008-05-09 EC EC2008008443A patent/ECSP088443A/es unknown
-
2011
- 2011-05-06 HR HR20110331T patent/HRP20110331T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2624588A1 (en) | 2007-04-19 |
| DE602006020634D1 (de) | 2011-04-21 |
| RU2008118365A (ru) | 2009-11-20 |
| BRPI0617215A2 (pt) | 2011-07-19 |
| ECSP088443A (es) | 2008-06-30 |
| IL190523A0 (en) | 2008-11-03 |
| ATE500849T1 (de) | 2011-03-15 |
| AU2006301331A1 (en) | 2007-04-19 |
| JP5060486B2 (ja) | 2012-10-31 |
| CA2624588C (en) | 2014-05-20 |
| EP1991271B1 (en) | 2011-03-09 |
| MY145269A (en) | 2012-01-13 |
| JP2009511543A (ja) | 2009-03-19 |
| KR20080055960A (ko) | 2008-06-19 |
| WO2007042469A2 (en) | 2007-04-19 |
| NZ567221A (en) | 2010-06-25 |
| WO2007042469A3 (en) | 2007-11-29 |
| RU2434876C2 (ru) | 2011-11-27 |
| NO20081619L (no) | 2008-07-03 |
| EP1991271A2 (en) | 2008-11-19 |
| PL1991271T3 (pl) | 2011-08-31 |
| AU2006301331B2 (en) | 2011-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110331T1 (hr) | Antikoagulantno-antitrombotski dvojni inhibitori, koji sadrže biotinski biljeg | |
| WO2007042470A3 (en) | Antithrombotic compound | |
| BRPI0508461B8 (pt) | diaminopirimidinas, seus usos, e composição farmacêutica | |
| CA2293415C (en) | Compositions for treating and preventing arterial thrombosis and use of a factor xa inhibitor on its own and/or combined with a platelet antiaggregating agent | |
| BRPI0507617A (pt) | antagonistas de receptor de quimiocina | |
| CN101454281A (zh) | 前列腺素ep4激动剂 | |
| BRPI0507345A (pt) | composto antitrombótico | |
| HRP20110330T1 (hr) | Antitrombotski dvojni inhibitori, koji sadrže biotinski ostatak | |
| JP2009511543A5 (hr) | ||
| AR078082A1 (es) | Composiciones farmaceuticas que comprenden fucanos modificados, metodos y kits relacionados | |
| UA94593C2 (ru) | Антитромбозные двойные ингибиторы с биотиновой меткой | |
| BR0115306A (pt) | Composto, prodroga, composição farmacêutica, agente para diminuir androgênio, método para a produção de um composto, e, sal diastereomérico | |
| HUP0102042A1 (hu) | Új pentaszacharidok, előállítási eljárásuk, valamint az ezeket tartalmazó gyógyszerkészítmények | |
| NL2031742B1 (en) | Pseudo-Disaccharide Compounds | |
| PL216486B1 (pl) | Zastosowanie kwasu fenylo-1,4-diaminobis(metylidenobisfosfonowego) w preparacie farmaceutycznym | |
| DOP2004000918A (es) | Profarmaco inhibidor de beta-lactamasa |